Table 1.

Pharmacogenetic studies on TNF blockers investigating TNF -308A/G polymorphism and HLA DRB1 shared epitope.

Authors (Ref)	Evaluation criteria	Patients, N (Ethnicity)	TNF blocker (Disease)	TNF -308A/G	Shared Epitope
Padyukof et al. (1)	ACR20 and/or DAS28/M3	123 (Cau)	ETN (RA)	No association	ND
Criswell et al. (2)	ACR50/M12	151 (Cau)	ETN (RA)	No association	Associated with better response
Mascheretti et al. (3)	CD activity score/W4	90 + 444 (Cau)	IFX (CD)	No association	ND
Mugnier et al. (4)	DAS28/W22	59 (Cau)	IFX (RA)	GG better responders	ND
Fonseca et al. (8)	DAS28/M24	22 (Cau)	ETN (RA)	GG better responders	ND
Kang et al. (9)	ACR70 vs non ACR20/W12	70 (Asi)	ETN (RA)	No association	No association
Marotte et al. (11)	ACR20/W30	198 (Cau)	IFX (RA)	No association	No association
Seitz et al. (12)	DAS28/W24	54 (Cau)	ETN, IFX, ADA (RA, PsA, AS)	GG better responders	ND
Our study	ACR50/W12	380 (Cau)	ADA (RA)	No association	No association

Ref: references

M: month

W: week

Cau: Caucasian

Asi: Asian

CD: Crohn disease

PsA: Psoriatic arthritis

AS: ankylosing spondylitis

ETN: etanercept

IFX: infliximab

ADA: adalimumab

ND: not done

DAS: disease activity status

ACR20, ACR50, ACR70: 20%, 50%, 70% improvement according to the American College of Rheumatology (ACR) criteria

RA: rheumatoid arthritis